8月19日，贝斯美（300796）（300796）发布2025年半年度报告，上半年公司实现营收7.76亿元，同比 增长16.57%；归母净利润3470.64万元，同比增长109.70%；扣非净利润3287.01万元，同比增长 125.95%；基本每股收益0.1元/股，同比增长100.00%。 随着环保农药产业政策持续释放红利，叠加公司在技术研发、品牌积淀等多维度构筑的强劲市场竞争 力，共同构成了贝斯美自产农药业务持续稳健增长的核心动能；子公司捷力克凭借在全球农药流通领域 积累的丰富专业经验、成熟营销网络，以及数量众多的海外农药登记证等先发优势，有力助推公司农药 出海业务拓展，形成了自产与出口协同并进的良好发展格局。同时，公司依托戊酮装置及间戊二烯原材 料预处理技术切入碳五新材料领域，把握高端产品进口替代机遇，构筑差异化壁垒。多板块协同发力， 为贝斯美持续拓展市场空间、实现高质量发展奠定坚实基础。 强链补链筑基，以绿色发展引领农药行业未来 随着农业现代化进程加速与绿色发展理念深化，高效、安全、经济、环境友好的农药新产品推广，已成 为推动农业可持续发展的关键抓手。中研普华产业研究院《"十四五"农药行业发展形势研究 ...

长江商报奔腾新闻记者 江楚雅 随着全球农药市场景气度提升，新型农药企业贝斯美业绩持续增长。 长江商报奔腾新闻记者注意到，2024年，受核心业务周期性影响，公司净利润出现显著亏损。2024年， 公司实现营业总收入13.28亿元，同比增长89.97%；但归属净利润亏损3286.46万元，同比下降 137.17%，扣非净利润亏损3603.61万元，同比下降142.58%。 此后，公司加码产品结构优化和渠道布局，业绩实现回暖。2025年一季度业绩实现扭亏，营收及净利润 同比双增，基本面改善显著。一季度公司实现营业收入为4.23亿元，同比增长19.35%；净利润为 2598.15万元，同比增长29.10%；扣非净利润为2408.81万元，同比增长32.92%。 业绩大幅回升的同时，公司加码产能扩建。6月10日，贝斯美在投资者互动平台表示，当前公司二甲戊 灵原药产能为年产12000吨。公司正在积极推进年产6000吨二甲戊灵扩产项目，该项目已完成政府审批 手续，预计扩产后总产能将达到18000吨/年，以更好承接海外市场需求。同时，公司的年产8500吨戊酮 系列绿色新材料项目已顺利投产，进一步强化上游产业链协同。 值得一提的 ...

Group 1 - The company expects a net profit of between 33.11 million and 44.42 million RMB for the current reporting period, representing a year-on-year growth of 100.07% to a decline of 168.38% [1] - The net profit attributable to shareholders is projected to be 16.55 million RMB, with a significant increase of 105.33% to a decline of 183.05% compared to the same period last year [1] - The preliminary financial data has been communicated with the auditing firm, and there are no significant discrepancies regarding the performance forecast [1][2] Group 2 - The company has optimized its product structure and achieved significant results from the layout of new products and international trade channels, leading to a substantial increase in profits from trade-related products in the first half of 2025 [2] - The gross profit from the "8,500 tons of ketone series green materials" project has turned positive, contributing to the overall performance improvement [2] - The specific financial data will be detailed in the company's 2025 semi-annual report, and investors are advised to make cautious decisions [2]

Core Viewpoint - The company Beishimei (300796) expects a significant increase in net profit for the first half of 2025, driven by product optimization and successful international trade channel development [1] Financial Performance - The projected net profit attributable to shareholders for January 1 to June 30, 2025, is estimated to be between 33.11 million yuan and 44.42 million yuan, compared to 16.55 million yuan in the same period last year, representing a year-on-year growth of 100.07% to 168.38% [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 29.87 million yuan and 41.18 million yuan, up from 14.55 million yuan in the previous year, indicating a growth of 105.33% to 183.05% [1] Drivers of Growth - The growth in performance is primarily attributed to the optimization of product structure, the successful introduction of new products, and the effective establishment of international trade channels [1] - There has been a significant increase in profits from trade-related products, and the gross profit margin for the fundraising project "8500 tons of ketone series green new materials" has turned positive [1]

Group 1: Company Overview and Strategic Projects - Shaoxing Bestmay Chemical Co., Ltd. is actively expanding its product lines in the C5 chemical sector, including the "Annual Production of 8,500 Tons of Ketone Series Green New Materials Project" and the "Annual Production of 12,100 Tons of Cyclopentane Series Green New Materials Project" [1][2][3] - The company has achieved stable operation of its ketone facility, with product quality meeting standards and sales status being steady [2][3] - The company is positioned as a leader in the domestic C5 comprehensive utilization field, enhancing its product offerings and reducing reliance on imports [2][3] Group 2: Financial Performance and Growth - In 2024, the company reported a revenue of 1.328 billion RMB, representing a year-on-year growth of 89.97% due to the full-year consolidation of Ningbo Jielike's operations following an 80% stake acquisition [5][6] - The revenue from C5 series products increased from 11.67 million RMB in 2023 to 73.12 million RMB in 2024, marking a growth of 5.26 times [20] Group 3: Research and Development - The company invested 45.52 million RMB in R&D in 2024, a 13.7% increase from the previous year, and holds 58 authorized patents, including 32 invention patents [6][8] - The focus on R&D has led to the development of proprietary technologies that enhance production efficiency and reduce costs, such as low-temperature continuous nitration and solid salt recovery technologies [18] Group 4: Market Position and Competitive Advantage - The company is recognized as a national high-tech enterprise and has established a complete production and R&D capability for the herbicide Dimethenamid-P, covering the entire industry chain from intermediates to formulations [8][15] - The company has a strong export presence, with its subsidiary Jielike operating in 79 countries, achieving over 75% of its revenue from overseas markets in 2024 [15][19] Group 5: Future Outlook and Strategic Initiatives - The company plans to continue focusing on environmentally friendly pesticide development and expand its C5 new materials product line to enhance market share and profitability [5][15] - The company aims to leverage its existing market channels and the acquisition of Jielike to penetrate emerging markets in South America, Africa, and Southeast Asia, thereby increasing sales of Dimethenamid-P [11][15]